SubjectAcute myeloid leukemia
Positive transcription elongation factor b
Permanent link to this recordhttp://hdl.handle.net/20.500.12613/4788
MetadataShow full item record
Abstract© 2018 The Author(s). Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.
Citation to related workSpringer Science and Business Media LLC
Has partJournal of Experimental and Clinical Cancer Research
ADA complianceFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact email@example.com